Clinical Trials on Pancreatic Neuroendocrine Tumor G2 in New Zealand

Total 927 results

Columbia University
Pfizer

Completed

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Uveal Melanoma

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Metastatic Melanoma

United States
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
NYU Langone Health

Recruiting

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma | Unresectable Melanoma

United States
Philogen S.p.A.

Recruiting

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients (NeoDREAM)

Melanoma Stage IIIB/C

Spain, United States, Switzerland
BioVex Limited
Amgen

Completed

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Melanoma

United States, United Kingdom, Canada, South Africa
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma

Melanoma | Cancer

Canada, United States
Agenus Inc.

Suspended

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Advanced Melanoma

United States, Spain, United Kingdom, France, Germany, Switzerland, Belgium, Italy, Brazil, Russian Federation
Hoffmann-La Roche

Completed

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Malignant Melanoma

United States, Australia
Novartis Pharmaceuticals

Completed

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM)

Melanoma

United States, Belgium, Germany, Singapore, Italy, Australia, Netherlands, Sweden, Spain, Canada, Switzerland, Argentina, Brazil, China
GlaxoSmithKline

Terminated

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Melanoma

United States, Australia, Spain, Taiwan, Bulgaria, Estonia, Germany, Belgium, France, Sweden, Israel, Poland, Italy, Czechia, Switzerland, Korea, Republic of, Ireland, Canada, Argentina, Netherlands, Russian Federation, Ukraine, Aus... and more
Exicure, Inc.

Terminated

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Merkel Cell Carcinoma | Advanced or Metastatic Cutaneous Squamous Cell Carcinoma | Advanced or Metastatic Melanoma | Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Study of Kidney Tumors in Younger Patients

Renal Cell Carcinoma | Wilms Tumor | Clear Cell Sarcoma of the Kidney | Papillary Renal Cell Carcinoma | Kidney Medullary Carcinoma | Diffuse Hyperplastic Perilobar Nephroblastomatosis | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Renal Cell Carcinoma Associated With Xp11.2 Translocations... and other conditions

United States, Canada, Puerto Rico, Australia, New Zealand, Israel, Switzerland
Amgen

No longer available

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Unresected Stage IIIb to IVM1c Melanoma

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Targovax Oy

Completed

A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

Advanced or Unresectable Melanoma Progressing After PD1 Blockade

United States, Norway
Viralytics

Completed

Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02) (PXS-X02)

Malignant Melanoma

Australia
GlaxoSmithKline

Completed

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

Melanoma

Australia, France, Germany, United States, Italy
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Refractory Melanoma | HLA-A2 Positive Cells Present

United States
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Philogen S.p.A.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients (INTACT/MeRCI)

Melanoma Stage IV | Melanoma Stage III

United States
Lexicon Pharmaceuticals

Completed

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Carcinoid Syndrome

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Canada, Israel
Merck Sharp & Dohme LLC

Completed

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Melanoma

Australia, South Africa, Spain, Sweden
Mannkind Corporation

Completed

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Melanoma | Small Cell Lung Carcinoma | Gastric Cancer | Mesothelioma | Breast Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Thyroid Cancer | Liver Cancer | Biliary Tract Cancer | Esophageal Carcinoma | Pancreatic Carcinoma | Gallbladder Cancer | Anal Carcinoma | Testicular Cancer | Neuroendocrine Cancer | Colore... and other conditions

United States
Bristol-Myers Squibb

Completed

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Melanoma

South Africa, United States, Spain, France, Italy, Belgium, Austria, Israel, Germany, Norway, Canada, Brazil, Poland, Denmark, Czech Republic, Russian Federation, Ukraine, Argentina
Bristol-Myers Squibb

Withdrawn

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA)

Melanoma

France, Italy, Poland, United States, Brazil, Spain, Australia, Denmark, Germany, Austria, Netherlands, Russian Federation, Belgium, United Kingdom, Sweden, Switzerland
Eisai Inc.
Quintiles, Inc.

Completed

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Stage IV Melanoma

United Kingdom, United States, Spain, Germany, Italy
Hoffmann-La Roche

Completed

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma (BRIM8)

Melanoma

United States, Israel, Italy, Spain, Belgium, United Kingdom, Austria, Czechia, France, Netherlands, New Zealand, Russian Federation, Australia, Canada, Croatia, Portugal, Germany, Ukraine, Switzerland, Argentina, Brazil, Ireland, N... and more
Evaxion Biotech A/S
Novotech (Australia) Pty Limited

Terminated

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Melanoma Stage IV | Melanoma Stage III

Australia
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)

Melanoma

Canada, Australia, Germany, Italy, Poland, France, Denmark, Argentina, Chile, Spain, Norway, Israel, Sweden, Mexico, Greece, Finland
Celgene

Completed

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Diffuse Large B-Cell Lymphoma | Multiple Myeloma | Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Glioblastoma Multiforme | Neuroendocrine Tumors of Non-Pancreatic Origin | Hormone Receptor-Positive Breast Cancer

United States, Spain, United Kingdom, France
Incyte Corporation

Active, not recruiting

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Melanoma

United States, Australia
Amgen

Completed

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma

United States, Poland, France, Russian Federation, Spain, Australia, Greece, Switzerland, Brazil
Synta Pharmaceuticals Corp.

Completed

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Melanoma

United States
Centocor, Inc.
Janssen-Cilag Farmaceutica, S.R.L.

Completed

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Melanoma

United States, United Kingdom, Germany
GlaxoSmithKline

Completed

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Cancer

Australia, Spain, United States, Germany, Poland, Italy, Canada, Ireland, Hungary, Russian Federation, Netherlands, France
Tarveda Therapeutics

Completed

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Carcinoma, Small Cell Lung

United States, United Kingdom
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma

Melanoma | Health Status Unknown | Dysplastic Nevus | No Evidence of Disease

United States
NCIC Clinical Trials Group

Completed

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Melanoma

Canada, United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Uveal Melanoma

United Kingdom, France, Netherlands, United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

Newly Diagnosed or Recurrent Metastatic Melanoma Patients | Malignant Brain Tumors

United States
Bristol-Myers Squibb

Completed

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Melanoma

Australia, France, Italy, Poland, United Kingdom, United States, Spain, Belgium, Denmark, Germany, Norway, Switzerland, Argentina, Austria, Sweden, Czechia, Hungary, Netherlands, Mexico, Canada, Israel, South Africa
Amgen
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (MASTERKEY-265)

Melanoma

United States, Finland, France, Germany, Italy, Canada, Czechia, Poland, Switzerland, Korea, Republic of, Russian Federation, United Kingdom, Australia, Netherlands, Spain, Austria, Belgium, Hungary, Portugal, Greece, South Africa
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
AstraZeneca

Completed

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

Melanoma

United States, Australia, Brazil, United Kingdom, Argentina, Austria, Canada, Denmark, France, Switzerland
Monte Rosa Therapeutics, Inc

Recruiting

Study of Oral MRT-2359 in Selected Cancer Patients

NSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast Cancer

United States, Canada
Hoffmann-La Roche

Completed

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma

Spain, United States, Belgium, Denmark, Canada, Australia
Seagen Inc.

Recruiting

A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Colorectal Neoplasms | Pancreatic Neoplasms | Mesothelioma | Non-small Cell Lung Cancer | Cutaneous Melanoma

United States, Canada, Switzerland, France, Germany, United Kingdom
Celldex Therapeutics

Terminated

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Melanoma

United States
Icahn School of Medicine at Mount Sinai
Patient-Centered Outcomes Research Institute

Completed

Improving Goals of Care Discussion in Advanced Cancer Patients

Melanoma | Glioblastoma | Colorectal Cancer | Cancer of Pancreas | Cancer of Stomach | Head or Neck Cancer | Stage III | Esophageal | Stage IV | Lung Cancers | Pancreatic Cancers | Primary Stage IV Hepatobiliary

United States

Clinical Trials on Pancreatic Neuroendocrine Tumor G2 in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations